EC Pulmonology and Respiratory Medicine

Objectives: To determine the difference of serum 25-(OH) D level between COPD patients and healthy people, and analyze the correlation between serum 25-(OH) D level and CAT score of COPD patients.

Methods: 1. Select 122 patients with COPD who visited our hospital from December 2021 to December 2022, including 62 patients in the AECOPD group, 60 patients in the stable COPD group, and 60 healthy people in our hospital during the same period as the control group, analyze the difference of 25-(OH) D among the above three groups of subjects, and analyze the correlation between 25-(OH) D level and CAT score of COPD patients by linear correlation method.

Results: 1. The level of 25-(OH) D in AECOPD group and stable COPD group was significantly lower than that in control group (P; The vitamin D deficiency rate in AECOPD group and stable COPD group was significantly higher than that in control group (P; 2. According to the correlation analysis, the level of 25-(OH) D in AECOPD group and stable COPD group was negatively correlated with CAT score (P < 0.05).

Conclusion: 1. The level of serum 25-(OH) D in patients with COPD was significantly reduced, and AECOPD patients had a high vitamin D deficiency rate; 2. Vitamin D deficiency has a negative impact on the quality of life of COPD patients.

Keywords: COPD; 25-(OH)D; Vitamin D Deficiency; CAT Score; Quality of Life

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 REPORT) [EB/OL] (2019).
2. GBD Chronic Respiratory Disease Collaborators. “Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017”. The Lancet Respiratory Medicine 6 (2020): 585-596.
3. Romme EA., et al. “Vitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary disease”. Annals of Medicine 1 (2013): 91-96.
4. Wang C., et al. “Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study”. Lancet10131 (2018): 1706-1717.
5. EMMA LC. “Vitamin D status is associated with muscle strength and quality of life in patients with COPD:a seasonal prospective observation study”. International Journal of COPD 13 (2018): 2613-2622.
6. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2021 report [OL] (2020).
7. Jackon AS., et al. “Vitamin D and skeletal muscle strength and endurance in COPD”. European Respiratory Journal 2 (2013): 309-316.
8. Holick MF. “The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention”. Reviews in Endocrine and Metabolic Disorders2 (2017): 153-165.
9. Wim J., et al. “Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene”. Thorax3 (2010): 215-220.
10. Wells JM., et al. “Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPD Gene”. JCI Insight22 (2018).
11. Jolliffe DA., et al. “Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials”. Thorax4 (2019): 337-345.
12. Greiller CL., et al. “Vitamin D attenuates rhinovirus-induced expression of intercellular adhesion molecule-1 (ICAM-1) and platelet-activating factor receptor (PAFR) in respiratory epithelial cells”. The Journal of Steroid Biochemistry and Molecular Biology 187 (2019): 152-159.
13. Hejazi M., et al. “A review of Vitamin D effects on common respiratory diseases: Asthma, chronic obstructive pulmonary disease, and tuberculosis”. Journal of Research in Pharmacy Practice1 (2016): 7.
14. Mekov E., et al. “Vitamin D Deficiency and Insufficiency in Hospitalized COPD Patients”. PLOS ONE6 (2015): e129080.
15. Paliogiannis P., et al. “Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives”. European Respiratory Review147 (2018): 170113.
16. Zhu M., et al. “The association between vitamin D and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysis”. 11 (2016): 2597-2607.
17. Lehouck A., et al. “High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial”. Annals of Internal Medicine 2 (2012): 105-114.
18. Martineau AR., et al. “Vitamin D 3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial”. The Lancet Respiratory Medicine2 (2015): 120-130.
19. Cheng SL., et al. “Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients”. Journal of the Formosan Medical Association 1-3 (2019): 429-435.
20. Makuch M., et al. “The relationship between COPD Assessment Test (CAT) scores and Distress Thermometer (DT) results in COPD patients”. Annals of Agricultural and Environmental Medicine 4 (2020): 689-694.
21. Yang H., et al. “Effects of Vitamin D on Respiratory Function and Immune Status for Patients with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review and Meta-Analysis”. Computational and Mathematical Methods in Medicine (2022): 1-14.